Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Arsenic trioxide oral - SDK Therapeutics

Next Previous
Drug Profile

Arsenic trioxide oral - SDK Therapeutics

Alternative Names: SDK 001

Latest Information Update: 04 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SDK Therapeutics
  • Class Anti-inflammatories; Antineoplastics; Arsenicals; Ischaemic heart disorder therapies; Oxides; Skin disorder therapies; Small molecules
  • Mechanism of Action Apoprotein stimulants; Apoptosis stimulants; Endothelial cell modulators; Immunostimulants; Thioredoxin reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute promyelocytic leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Acute promyelocytic leukaemia

Most Recent Events

  • 05 May 2025 SDK Therapeutics plans a global phase III registration trial for Acute promyelocytic leukaemia, in the third quarter of 2025 (SDK Therapeutics website, May 2025)
  • 18 Mar 2025 Phase-I/II clinical trials in Acute promyelocytic leukaemia in Hong Kong (PO) (NCT06882031)
  • 31 Jan 2025 The US FDA approves IND application for SDK 001 in Acute promyelocytic leukaemia (SDK Therapeutics website, May 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top